Prohormone convertases 1 (PC1) and 2 (PC2) are members of a family of subtilisin-like proprotein convertases responsible for proteolytic maturation of a number of different prohormones and proneuropeptides. Although sharing more than 50% homology in their catalytic domains, PC1 and PC2 exhibit differences in substrate specificity and susceptibility to inhibitors. In addition to these differences, PC2, unlike PC1 and other members of the family, specifically binds the neuroendocrine protein 7B2. In order to identify determinants responsible for the specific properties of the PC2 catalytic domain, we compared its primary sequence with that of other PCs. This allowed us to distinguish a PC2-specific sequence at positions 242-248. We constructed two PC2 mutants in which residues 242 and 243 and residues 242-248 were replaced with the corresponding residues of PC1. Studies of in vivo cleavage of proenkephalin, in vivo production of ␣-MSH from proopiomelanocortin, and in vitro cleavage of a PC2-specific artificial substrate by mutant PC2s did not reveal profound alterations. On the other hand, both mutant pro-PC2s exhibited a considerably reduced ability to bind to 21-kDa 7B2. In addition, inhibition of mutant PC2-(242-248) by the potent natural inhibitor 7B2 CT peptide was almost completely abolished. Taken together, our results show that residues 242-248 do not play a significant role in defining the substrate specificity of PC2 but do contribute greatly to binding 7B2 and are critical for inhibition with the 7B2 CT peptide.
1
is responsible for the proteolytic maturation of a number of different prohormones and neuropeptide precursors (reviewed in Refs. [1] [2] [3] . To date, seven members of this family have been identified in mammals. All share a common basic domain structure consisting of an N-terminal signal peptide, a poorly conserved propeptide, a highly conserved catalytic domain with the typical subtilisin catalytic triad, a well conserved middle or P, domain, and a highly variable Cterminal region (2, 3) . No crystal structure is available thus far for the SPCs. Two members of the family, prohormone convertase 1 (PC1) and 2 (PC2), are expressed exclusively in neural and endocrine tissues (reviewed in Ref. 1) . Synthesized as full-length inactive proproteins (pro-PCs), both PC1 and PC2 undergo autocatalytic propeptide cleavage to yield mature active forms (4 -10) . PC1, but not PC2, is further slowly cleaved C-terminally to generate a PC1 form with increased activity (6, (11) (12) (13) . The PC1 propeptide has been shown recently to represent a very potent inhibitor of this enzyme (14) , a finding characteristic of subtilases (1, 15) . The PC2 propeptide is correspondingly expected to inhibit PC2, and recent data indicate that this is indeed the case. 2, 3 PC1 and PC2 have distinct, although overlapping, substrate specificities. The two enzymes most often cleave precursors at pairs of basic residues (2, 3), but both are also capable of cleaving at a single Arg residue (16 -18) . The presence of a basic residue at position P4 is favored by both enzymes for cleavage of an artificial substrate (19 -21) . However, the two enzymes show important differences in specificity as regards natural substrates; processing of endogenous substrates such as proenkephalin (PE), proopiomelanocortin (POMC), proglucagon, procholecystokinin, proneurotensin, and promelaninconcentrating hormone by PC1 or by PC2 results in differing product patterns (12, (22) (23) (24) (25) (26) (27) (28) (29) (30) . In the majority of the studies performed to date, PC1 exhibits a more restricted substrate specificity than PC2. Although models of the active sites of PC1 and PC2 have been proposed based on the known x-ray structure of subtilisin (31) , the amino acid residues responsible for the different substrate specificities of these enzymes have not been identified thus far.
Unlike other members of the family, pro-PC2 requires interaction with the neuroendocrine-specific protein 7B2 for its maturation and activation (32) (33) (34) (35) (36) (37) . 27-kDa 7B2 is cleaved within the trans-Golgi network into an amino-terminal 21-kDa domain (21-kDa 7B2; residues 1-135) and a C-terminal peptide of 31 residues (CT peptide) (38, 39) . The CT peptide represents a very potent in vitro inhibitor of PC2 as does the parent 27-kDa 7B2 molecule (40 -42) . Recent attempts to demonstrate the ability of overexpressed CT peptide to inhibit PC2 in vivo were not, however, successful due to intracellular internal cleavage of this peptide (43) . Inhibition of PC2 by the 7B2 CT peptide strongly depends on the presence of a K-K site (40, 42) ; other residues within the peptide are also critical to inhibitory potency (44) . No information is available thus far on which PC2 residues confer the ability to be inhibited by the CT peptide; presumably, these residues are not shared by PC1, which is not inhibited by this peptide (45) .
In contrast to the CT peptide, the 21-kDa domain of 7B2 appears to be the portion of 7B2 responsible for pro-PC2 maturation and activation (32) . Within this domain, a fragment encompassing residues 86 -121 contains all of the information required for 7B2-mediated activation of pro-PC2 (46) . Studies aimed at defining the structural elements of PC2 required for interaction with 7B2 have identified two residues in the catalytic domain of PC2, Tyr 194 and Asp 309 , that are apparently critical to the PC2-7B2 binding (47) (48) (49) . However, it is likely that other residues also play an important role in this interaction.
The present study is aimed at defining the residues in the active site of PC2 that contribute to the unique characteristics of this enzyme as opposed to PC1, such as its comparatively broad substrate specificity, its ability to bind to 7B2, and its potent inhibition by CT peptide. For this purpose, the primary sequences of several PC1, PC2, and furin enzymes from different species were aligned, and the residues within the predicted substrate binding sites (15, 31, 50) were compared. This analysis revealed that in positions 242-248 (numbering is that of PC2), PC2s contain the sequence QP(Y/F)MTD(L/I), which differs considerably from the corresponding sequence in PC1s and furins, G(I/E)VTDA (Fig. 1) . It is noteworthy that both PC1s and furins contain a deletion in this sequence as compared with PC2s; the single G residue in PC1s and furins thus corresponds to the QP residues of PC2s (positions 242 and 243). The residues in this region (positions 242-248) are located within or in the vicinity of subsites S2-S5 of prohormone convertases, according to homology modeling of protein convertases based on the crystal structure of subtilisin (50, 31) . These residues could thus contribute to PC2-specific properties. In the present study, we constructed two murine PC2-related mutants: PC2-(242-243), in which residues QP were replaced with the corresponding G residue found in PC1, and PC2-(242-248), in which the murine PC1 sequence GIVTDA was substituted for the corresponding sequence QPFMTDI of PC2. We report below that these mutations result in significant loss of binding of 7B2 to pro-PC2 as well as substantial loss of inhibition of PC2 with the 7B2 CT peptide.
EXPERIMENTAL PROCEDURES
Materials-The human 7B2 CT peptide (encompassing 7B2 residues 155-185) and a murine PC2 propeptide fragment (residues 57-84, SLHHKRQLERDPRIKMALQQEGFDRKKR) were synthesized by LSUHSC Core Laboratories (New Orleans, LA). pERTKR-MCA was purchased from Peptides International (Louisville, KY). Ac-LLRVKR-NH 2 (51) was kindly provided by J. Appel and R. A. Houghten (Torrey Pines Institute for Molecular Studies, San Diego, CA). The internally quenched fluorogenic substrate Abz-VPEMEKRYGGFMQ-EDDnp (20) was kindly provided by L. Juliano (Department of Biophysics, Escola Paulista de Medicina, San Paolo, Brazil).
Construction of PC2 Mutants-Mouse PC2 cDNA (obtained from Dr. N. G. Seidah, Clinical Research Institute of Montreal, Montreal, Canada) was first subcloned through blunt-end ligation into the pcDNA3 vector cut at the KpnI site, and this plasmid was used in constructing PC2 mutants. Mutants were generated by synthesizing mutation-containing fragments by polymerase chain reaction and subcloning the polymerase chain reaction-generated fragments into mPC2/pcDNA3 between the HindIII and Bsu36I sites. The mutants were constructed using the same amino-terminal and carboxyl-terminal primers, 5Ј-CG-CGCAAGCTTTTTCACTCCCAAAGAAGG-3Ј and 5Ј-GCCGGCCTCAG-GATTCCTCTTCCTCCCATT-3Ј, respectively. The middle primers were as follows: for mutant PC2-(242-248), 5Ј-GACGGGATTGTGACAGAC-GCCATCGAAGCCTCCTCCATC-3Ј and 5Ј-GATGGCGTC TGTCACAA-TCCCGTCCAGCATCCGGATCCC-3Ј; for mutant PC2-(242-243), 5Ј-G-ACGGGTTTATGACAGATATCATCGAAGCCTCCTCCATC-3Ј and 5Ј-GATGATATCTG TCATAAACCCGTCCAGCATCCGGATCCC-3Ј. Expand High Fidelity Taq polymerase (Roche Molecular Biochemicals) was used in all polymerase chain reactions. The fidelity of polymerase chain reaction-generated fragments was verified by DNA sequencing. The PC2, PC2-(242-243), and PC2-(242-248) constructs in pCEP4 were obtained by recloning the corresponding PC2 cDNA from a pcDNA3 plasmid into pCEP4 (Invitrogen, Carlsbad, CA) at the HindIII and NotI sites using standard procedures.
Cell Culture and Transfection-Methotrexate-amplified CHO/21-kDa 7B2 cells that express large quantities of 21-kDa 7B2 were generated by the same procedure described earlier (52) . The cells were maintained in ␣-minimum essential medium without nucleosides, containing 10% dialyzed fetal bovine serum (Irvine Scientific, Santa Ana, CA) and 50 M methotrexate (Sigma). AtT-20/27-kDa 7B2, AtT-20/PE, and AtT-20/PC2 cells, representing AtT-20 cell lines stably expressing rat 27-kDa 7B2 (32), rat proenkephalin (22) , and murine wild-type PC2 (12) , respectively, were cultured in Dulbecco's modified Eagle's medium (high glucose) (Life Technologies, Inc.) containing 10% NuSerum (Becton Dickinson, Mountain View, CA), 2.5% fetal bovine serum, and either 200 g/ml hygromycin (Sigma) (for AtT-20/7B2 cells) or 150 g/ml G418 (Life Technologies). CHO/21-kDa 7B2, AtT-20/27-kDa 7B2, and AtT-20/PE cell lines served as hosts for stable transfection of the PC2 constructs described above. All transfections were performed using 30 g of plasmid and 30 l of Lipofectin (Life Technologies) in a 10-cm dish. Transfected cells were then cultured in the presence of the appropriate selection agent (250 or 450 g/ml G418 (for CHO/21-kDa 7B2 and AtT-20/27-kDa 7B2 cells, respectively) or 200 g/ml hygromycin). G418-or hygromycin-resistant colonies were picked and screened for PC2 expression by Western blotting using PC2 antiserum (53) or by enzyme assay with pERTKR-MCA as the substrate.
Production and Partial Purification of PC2 Proteins-Partially purified wild-type PC2, PC2-(242-248), and PC2-(242-243) were obtained from the conditioned media of the CHO/21-kDa 7B2 cells stably expressing the corresponding 75-kDa pro-PC2 protein. Sequential collections of the conditioned medium from the confluent roller bottles were performed every morning, 5-7 days in a row, after placing the cells into 100 ml of Opti-MEM (Life Technologies Inc.) containing 100 g/ml aprotinin (Bayer) overnight (usually 18 -19 h); during the day, the cells were kept in complete medium (␣-minimum essential medium without nucleosides, containing 10% dialyzed fetal bovine serum, 50 M meth-
FIG. 1.
Comparison of the amino acid sequences of PC2, PC1, and furin enzymes. The region consisting of residues 240 -254 (numbering is that of mouse PC2) is shown. The PC1 sequence shown is shared by human, pig, mouse, and rat PC1 enzymes. The furin sequence shown is shared by human, mouse, rat, and hamster furins. The sequence shown for mouse PC2 is also shared by rat, human, and pig PC2s. The sequence shown for D. melanogaster PC2 is also shared by C. elegans PC2. The residue substitutions in PC2-(242-243) and PC2-(242-248) are underlined and in boldface type.
otrexate, and 250 g/ml G418). The conditioned media were centrifuged immediately after collection at low speed to remove floating cells, and the supernatants were stored at Ϫ70°C until needed. For purification, 100 -200 ml of the medium were used. The medium was thawed and centrifuged at 15,000 ϫ g for 15 min, and the supernatant was diluted 3-fold with buffer A (20 mM Bis-Tris buffer, pH 6.65, containing 0.1% Brij 35). Diluted medium was applied onto a 5-ml Econo-Pack TM Q Cartridge (Bio-Rad) equilibrated with buffer A. The column was washed with buffer A and eluted at a flow rate of 0.5 ml/min with buffer B (1 M sodium acetate in buffer A) using two linear gradients, from 0 to 0.35 M in 175 min and from 0.35 to 1 M in 100 min.
Enzyme Assays-Duplicate reactions were performed in a polypropylene microtiter plate in a total volume of 50 l, containing 100 mM sodium acetate buffer, pH 5.0, 5 mM CaCl 2 , 0.4% n-octyl glucoside, an inhibitor mixture (0.14 mM (4-guanidino) butane (Sigma), and 1 M pepstatin (Sigma)), 0.2 mM fluorogenic substrate pERTKR-MCA, and 5 l of the partially purified enzyme. Reactions to test the peptide inhibitors (human 7B2 CT peptide, the PC2 propeptide fragment, or the hexapeptide Ac-LLRVKR-NH 2 ) also contained varying amounts of these peptides. Prior to the addition of the peptide inhibitor (if used) and the substrate, the partially purified enzyme was preincubated in the assay buffer at 37°C for 30 -40 min. After the peptide inhibitor was added, the reaction mixtures were preincubated at room temperature for 30 min, followed by the addition of substrate. All reactions were conducted at 37°C for 30 -45 min. Released 7-amino-4-methylcoumarin was measured with a Fluoroscan Ascent fluorometer (Labsystems) using an excitation and an emission wavelength of 380 and 460 nm, respectively. The IC 50 values for the peptide inhibitors were calculated through nonlinear regression of the experimental data (fluorescence versus peptide concentration) using the program GraphPad (GraphPad Software, Inc., San Diego, CA).
pH Dependence of Enzymatic Activity of PC2s-The effect of varying pH on the activity of partially purified PC2 enzymes was determined by measuring the rate of hydrolysis of 0.2 mM pERTKR-MCA in 100 mM Bis-Tris, 100 mM sodium acetate buffer set at different pH values (ranging from 4.0 to 7.4) in the presence of 5 mM CaCl 2 , 0.4% octyl glucoside, and an inhibitor mixture (see above). Prior to the addition of the substrate to start the reaction, the assay mixtures were preincubated at 37°C for 30 -40 min for enzyme activation.
Time Course Conversion of Pro-PC2 Proteins-Partially purified wild-type pro-PC2, pro-PC2-(242-248), and pro-PC2-(242-243) were incubated at 30°C in 100 mM sodium acetate buffer, pH 5.0, in the presence of 5 mM CaCl 2 , 0.1% Brij 35, and an inhibitor mixture (see above). At varying time intervals, aliquots were frozen for subsequent analysis by SDS-PAGE and Western blotting using PC2 antiserum (53) .
Quantitation of PC2 Proteins in the Partially Purified Preparations-To determine the relative concentrations of PC2 protein in the various preparations, wild-type PC2, PC2-(242-248), and PC2-(242-243) were diluted into 100 mM sodium acetate buffer, pH 5.0, containing 5 mM CaCl 2 and 0.1% Brij 35, and two amounts (the second twice as much as the first) of each sample were applied onto a 10% gel. On the same gel were applied varying amounts of highly purified 66-kDa PC2 (diluted in the same buffer) with a known protein content. The samples were subjected to SDS-PAGE and Western blotting using PC2 antiserum (53) . Images of the blots were then obtained with a ScanJet 4C scanner (Hewlett Packard), and the intensities of the bands were compared using ImageQuant Software (Molecular Dynamics, Inc., Sunnyvale, CA). The PC2 concentration in each enzyme preparation was averaged from 2-4 independent experiments.
Determination of k cat /K m Values for an Internally Quenched Fluorogenic Substrate-The internally quenched substrate Abz-VPE-MEKRYGGFMQ-EDDnp (final concentration of 2 M) was subjected to digestion by partially purified PC2 or PC2-(242-248) in a buffer containing 200 mM sodium acetate, pH 5.0, 5 mM CaCl 2 , 0.4% octyl glucoside, and inhibitor mixture (see above) in a total volume of 50 l. The reactions were initiated by the addition of substrate and conducted for 2 h at 37°C in polypropylene microtiter plates. Abz fluorescence was recorded with a Fluoroscan Ascent fluorometer (Labsystems) using excitation and emission wavelengths of 320 and 420 nm, respectively. k cat /K m values were calculated based on the curves obtained, as described previously (20) .
Metabolic Labeling-Subconfluent wells of AtT-20/27-kDa 7B2 cells, expressing either wild-type PC2, PC2-(242-243), PC2-(242-248), or no exogenous PC2, and wells of AtT-20/PC2 cells, plated in six-well plates, were washed once with 3 ml of PBS and once with 1 ml of methionine and cysteine-free medium (ICN Biomedicals, Inc., Irvine, CA) containing 10 mM HEPES, pH 7.4, and were starved for 30 min in 1 ml of this medium. Cells were then incubated in 1 ml of methionine and cysteinefree medium containing 0.5 mCi/ml [ 35 S]methionine/cysteine (Promix, Amersham Pharmacia Biotech) for different time periods depending on the particular experiment. In the experiments to study production of ␣-MSH, cells were labeled for either 20 min or for 6 h. Following the 6-h labeling period, cells were homogenized in 1 ml of acid mix (1 M acetic acid, 20 mM HCl, and 0.1% ␤-mercaptoethanol). Following the experiment in which cells were pulse-labeled for 20 min, cells were further incubated in 1 ml of chase medium (Dulbecco's modified Eagle's medium containing 10 mM HEPES, pH 7.4, and 2% fetal bovine serum) for 1 h prior to homogenization in acid mix. Cell extracts in acid mix were frozen, thawed, and centrifuged at 14,000 ϫ g for 5 min. The supernatants were collected and lyophilized overnight. The dried cell extracts were resuspended in 500 l of AG buffer (100 mM sodium phosphate buffer, pH 7.4, 1 mM EDTA, 0.1% Triton X-100, 0.5% Nonidet P-40, and 0.9% NaCl), centrifuged briefly to remove insoluble material, and stored frozen at Ϫ20°C prior to immunoprecipitation using polyclonal rabbit antiserum JH93 directed against the N-terminal portion of ACTH (54) . To study binding of 7B2 to PC2s, cells were pulsed for 20 min and chased for 30 min, and cell extracts were prepared as described previously (46) . 7B2 and PC2 were immunoprecipitated from clarified cell extracts with antiserum LSU13 or LSU18 (directed against 7B2 and PC2, respectively; Ref. 32) . In order to characterize pro-PC2 autocatalytic conversion in vitro, cells were pulsed for 20 min, chased for 120 min in the presence of 1 M bafilomycin A1, an inhibitor of vacuolar ATPase, and extracted as described previously (34) . Pro-PC2 was immunoprecipitated from clarified cell extracts prior to a 30-min incubation at 37°C in 100 mM Bis-Tris, 100 mM sodium acetate buffer set at either pH 5 or pH 7. In the experiments to study intracellular maturation of pro-PC2s, cells were pulsed for 20 min, chased for 0 or 120 min, and then boiled for 5 min in 0.1 ml of boiling buffer (50 mM sodium phosphate, pH 7.4, 1% SDS, 50 mM ␤-mercaptoethanol, and 2 mM EDTA). Samples were then diluted with 0.9 ml of AG buffer for immunoprecipitation using antiserum LSU 18.
Immunoprecipitation-For immunoprecipitation using antiserum JH93, a 200-or 100-l aliquot of cell extract was incubated in AG buffer with 2.5 mg of prehydrated Protein A-Sepharose CL-4B beads (Amersham Pharmacia Biotech) in a final volume of 350 l for 1 h at 4°C with constant rocking. The samples were centrifuged for 2 min, and the supernatants were transferred to fresh tubes and incubated with antiserum JH93 (5-6 l) for 3 h at 4°C with constant rocking. Prehydrated Protein A-Sepharose CL-4B beads in AG buffer were then added into the supernatant, and the samples were further incubated for 1 h at 4°C. Samples were centrifuged for 2 min, and the beads were washed three times with 0.5 ml of AG buffer, once with 0.5 ml of 0.5 M NaCl, and once with 0.5 ml of PBS. Immunoprecipitated proteins were extracted from the beads by adding 120 l of 21% (v/v) acetonitrile, containing 0.07% trifluoroacetic acid, 6 M urea, and 0.33 M acetic acid, and incubating at room temperature for 15 min, followed by centrifugation for 2 min at 1,500 ϫ g. The supernatants were removed and stored frozen at Ϫ20°C prior to analysis by high pressure gel permeation chromatography (HPGPC). Immunoprecipitation of pro-PC2s and 7B2 was performed using antiserum LSU18 or LSU13 as described previously (34) . Immune complexes were boiled in Laemmli sample buffer, and proteins were separated by SDS-PAGE on 8.8 or 15% gels. Gels were exposed to a phosphoscreen and analyzed with a Storm PhosphorImager and ImageQuant software (Molecular Dynamics).
Proenkephalin Processing in Vivo-AtT-20/PE cells and AtT20/PE cells stably transfected with PC2, PC2-(242-243), or PC2-(242-248) were seeded in 10-cm dishes and grown until ϳ70 -80% confluent and then washed once with PBS and homogenized in 1 ml of acid mix on ice. The homogenates were frozen, thawed, and centrifuged for 5 min at 14,000 ϫ g. The clear supernatants were removed and lyophilized overnight. The dried cell extracts were resuspended in 250 l of 32% acetonitrile containing 0.1% trifluoroacetic acid and centrifuged at 14,000 ϫ g for 5 min to remove any insoluble material. The clear supernatants were removed and stored at Ϫ20°C. 100-l aliquots were size-fractionated by HPGPC, and the fractions obtained were subjected to radioimmunoassay using the Met-enk-Arg-Gly-Leu antiserum Cass (55) . Three different clones of each cell line were used in these experiments.
HPGPC-Samples were size-fractionated by HPGPC as described previously (23) . The system consisted of a TSK-GEL SW guard column (7.5 ϫ 7.5 mm; TosoHaas, Montgomeryville, PA) and two HPGPC columns connected in series, a Protein Pak SW 300 column (300 ϫ 7.8 mm; Waters, Milford, MA) and a Bio-Sil TSK-125 column (300 ϫ 7.5 mm; Bio-Rad). When radiolabeled proteins were separated by HPGPC, the radioactivity was detected on-line using a ␤-RAM R Flow-Through System, model 2 (IN/US Systems, Inc., Tampa, FL). Otherwise, 1-ml fractions were collected into polypropylene tubes each containing 50 g of bovine serum albumin to prevent absorption to tube walls and stored at Ϫ20°C. Aliquots of the fractions were subjected to radioimmunoassay using the Met-enk-Arg-Gly-Leu antiserum Cass.
Radioimmunoassay of Proenkephalin Digestion Products-Radioimmunoassay was carried out on HPGPC fractions obtained from cellular extracts; duplicate aliquots of the fractions either were directly diluted in 100 l of radioimmunoassay buffer (100 mM sodium phosphate, pH 7.4, containing 0.1% heat-treated bovine serum albumin, 50 mM NaCl, and 0.1% sodium azide) or in some assays were vacuum-dried in the presence of bovine serum albumin and then resuspended in 100 l of the same buffer (when the volume of an aliquot exceeded 6 l). The samples were then subjected to Met-enk-Arg-Gly-Leu radioimmunoassay as described previously (55) . All radioimmunoassays were performed twice with similar results.
Collection of Conditioned Medium from AtT-20 Cells-AtT-20/27-kDa 7B2 cells expressing either no PC2, wild-type PC2, PC2-(242-243), or PC2-(242-248) were seeded into a six-well plate (500,000 cells/well) and grown for 1 or 2 days until 60 -80% confluent. The wells were washed once in 3 ml of PBS and then incubated with 1 ml of Opti-MEM containing 100 g/ml aprotinin for 16 -17 h. The conditioned medium was removed from each well, centrifuged briefly to remove any floating cells, and stored at Ϫ20°C. The cells were washed twice with 2 ml of PBS and extracted with 350 -400 l of acid mix (see above) on ice, and acid suspensions were subjected to protein assay to correct for variations in cell growth. Ten l of duplicate aliquots of the conditioned medium were used for the enzyme assay, and 100-or 200-l aliquots were subjected to trichloroacetic acid precipitation and subsequent SDS-PAGE and Western blotting to compare the amounts of PC2s. The mixtures for the enzyme assay contained (in a 50-l volume) 100 mM sodium acetate, pH 5.0, 5 mM CaCl 2 , 0.4% octyl glucoside, an inhibitor mixture (see above), 10 l of conditioned medium, and 200 M fluorogenic substrate, pERTKR-MCA. The mixtures were incubated in a microtiter plate at 37°C for up to 16 h, and released 7-amino-4-methylcoumarin was measured with a Fluoroscan Ascent fluorometer using excitation/emission wavelengths of 380/460 nm.
Transient Transfection of HEK 293 Cells-HEK 293 cells were maintained in Dulbecco's modified Eagle's medium (high glucose), containing 10% fetal bovine serum. The cells were plated into six-well plates and grown until approximately 70 -80% confluent. The cells were then transiently transfected using 2 g of pro-PC2 (wild-type or mutant) expression vector and 5 l of LipofectAMINE (Life Technologies Inc.) or using 2 g of pro-PC2 (wild-type or mutant) expression vector along with 2 g of 21-kDa 7B2 cDNA and 10 l of LipofectAMINE in 1 ml of Opti-MEM per well. In control transfections, empty pcDNA3 vector was used instead of pro-PC2-encoding cDNAs. Approximately 24 h posttransfection 1 ml/well of Opti-MEM containing 100 g/ml aprotinin was placed on the cells for 16 -17 h. The conditioned medium was removed, centrifuged briefly to remove nonadherent cells, and concentrated 10 -16-fold at 4°C using a 30K Microcon or Centricon concentrating unit (Amicon). 10-l duplicate aliquots of the concentrated conditioned medium were used for the PC2 enzyme assay immediately following concentration. The assay conditions were identical to those used with AtT-20 cells (see above); reaction mixtures were incubated at 37°C for up to 24 h.
SDS-PAGE and Western Blotting-Samples for SDS-PAGE analysis were boiled for 2 min after the addition of 1 ⁄5 volume of 5ϫ Laemmli sample buffer. After electrophoresis on either 8.8 or 10% gels, the separated proteins were electroblotted onto nitrocellulose and subjected to Western blotting using PC2 antiserum directed against the last 13 amino acids of PC2 (53) .
Protein Assay-Protein concentrations were determined using the Bio-Rad Protein Assay (Bio-Rad), with bovine serum albumin as a standard.
RESULTS
In the present study, wild-type and mutant PC2s were characterized both in vitro and in vivo. For in vitro experiments, PC2s were partially purified from the conditioned media of the CHO/21-kDa 7B2 cells stably expressing the corresponding 75-kDa pro-PC2 protein. Using this expression system, we were able to obtain all three PC2s in relatively large quantities.
In vivo experiments were performed using AtT-20/27-kDa 7B2 or AtT-20/PE cells stably expressing wild-type and mutant pro-PC2s. These experiments allowed us to assess the intracellular effects of mutations in the context of a neuroendocrine cell type.
pH Dependence of Mutant PC2s-PC1 and PC2 have been shown to possess slightly different pH optima for fluorogenic substrate cleavage, namely a pH of about 5.0 for PC2 and pH 5.5-6.0 for PC1 (6, 13, 40, 56) . To determine if replacement of residues in the vicinity of the PC2 catalytic site with PC1 residues shifts the pH optimum toward the higher PC1 optimum, we directly compared the pH dependences of partially purified wild-type PC2, PC2-(242-248), and PC2-(242-243) toward the cleavage of the fluorogenic substrate pERTKR-MCA. As is evident in Fig. 2 , all three enzymes have similar pH dependence profiles, indicating that the mutated residues do not contribute to the lower pH optimum of PC2.
Maturation of Mutant Pro-PC2s-To determine if the mutations introduced affect pro-PC2 maturation, we first compared the intracellular processing of mutant and wild-type pro-PC2s in AtT-20/27-kDa 7B2 cells. Fig. 3A shows the results of an experiment in which cells were pulsed with [
35 S]methionine/ cysteine and then either immediately extracted or chased for 120 min prior to extraction. It is evident that maturation of pro-PC2-(242-248) as well as pro-PC2-(242-243) in these cells proceeds at a slower rate as compared with that of wild-type pro-PC2. In fact, the rates of maturation of mutant pro-PC2s are closer to the rate of maturation of wild-type pro-PC2 in AtT-20 cells expressing no exogenous 7B2.
To obtain insight into the nature of the slower intracellular maturation reaction of the mutant pro-PC2s, we immunoprecipitated radiolabeled wild-type pro-PC2 and pro-PC2-(242-248) from the same cells and incubated them at either pH 7.0 or pH 5.0 to assess in vitro maturation capability (Fig. 3B) . The results show that mutant pro-PC2 and wild-type pro-PC2 from AtT-20 cells co-expressing 7B2 considerably differ in their ability to autocatalytically convert at acidic pH. In contrast to wild-type PC2, virtually no mature PC2-(242-248) was detected after a 30-min incubation of the pro form at pH 5.0, indicating a highly reduced ability of the mutant to autoconvert. In this respect, this mutant pro-PC2 resembles wild-type pro-PC2 contained in AtT-20/PC2 cells expressing no exogenous 7B2. Conversion of wild-type pro-PC2 from AtT-20/PC2 cells proceeded at a significantly slower rate than wild-type pro-PC2 obtained from AtT-20/27-kDa 7B2/PC2 cells (Fig. 3B ) but was still higher than the rate of conversion of pro-PC2-(242-248).
We further compared the rates of autocatalytic conversion of wild-type and mutant pro-PC2s expressed in CHO/21-kDa 7B2 cells and partially purified from the conditioned media (Fig. 4) . Rates of maturation of the three pro-PC2s examined were more similar in this case than when the proteins were expressed in AtT-20/27-kDa 7B2 cells. With both wild-type PC2 and PC2-(242-248), 55-58% of the enzymes were represented by the mature 66-kDa form after a 5-min incubation. With PC2-(242-243), a slightly longer incubation (7.5 min) was required to obtain 52% of the enzyme as the mature form. It should be noted that some variability in the rate of autocatalytic conversion was observed between the two different preparations of pro-PC2-(242-248) we used in this experiment. With the second enzyme preparations, 50% conversion (ratio of PC2/(pro-PC2 ϩ PC2)) was observed after approximately 10 min of incubation (data not shown). Nevertheless, even taking into account this variability, we can conclude that when expressed in CHO/21-kDa 7B2 cells, the two mutant pro-PC2s do not exhibit profound alterations in the rate of autocatalytic conversion as compared with wild-type pro-PC2.
Activity of Mutant PC2s toward the Fluorogenic Substrate-We next examined whether the introduced mutations affect the catalytic activity of PC2 against the fluorogenic substrate pERTKR-MCA. In the conditioned medium of AtT-20/27-kDa 7B2 cells expressing different PC2s, the activity of both mutants proved to be considerably lower (by 5-10 times) than that of wild-type PC2, although PC2-(242-243) was more active than PC2-(242-248) (Fig. 5) .
Comparison of the specific activities of the PC2 enzymes partially purified from the conditioned medium of CHO/21-kDa 7B2/PC2 (wild-type or mutant) cells was performed using FIG. 4 . Autocatalytic conversion of mutant pro-PC2s expressed in CHO/21-kDa 7B2 cells. Wild-type pro-PC2, pro-PC2-(242-243), and pro-PC2-(242-248) partially purified from conditioned media of CHO/21-kDa 7B2 cells expressing the corresponding pro-PC2 were incubated at 37°C in 100 mM sodium acetate, pH 5.0, containing 5 mM CaCl 2 , 0.1% Brij, and an inhibitor mixture. At the time points indicated, aliquots were frozen for analysis by SDS-PAGE and Western blotting. The pro-PC2 and PC2 bands were quantitated, and the ratio of PC2/ (pro-PC2 ϩ PC2) was calculated and shown at the bottom of the Western blot.
FIG. 3. Maturation of mutant pro-PC2s expressed in AtT-20/27-kDa 7B2 cells.
A, intracellular processing of wild-type and the mutant pro-PC2s. AtT-20/wild-type PC2 cells expressing no endogenous 7B2 and AtT-20/27-kDa 7B2 cells expressing either wild-type PC2, PC2-(242-243), or PC2-(242-248) were pulsed for 20 min and chased for 0 or 120 min; extracts were subjected to immunoprecipitation with PC2 antiserum; and immunoprecipitates were analyzed by SDS-PAGE. Similar results were obtained in two independent experiments employing three independent clones for each mutant. B, autocatalytic conversion in vitro of wild-type pro-PC2 and pro-PC2-(242-248). AtT-20/wild-type PC2 cells expressing no endogenous 7B2 and AtT-20/27-kDa 7B2 cells expressing either wild-type PC2 or PC2-(242-248) were pulsed for 20 min and then chased for 120 min in the presence of bafilomycin A1. Proteins were immunoprecipitated using PC2 antiserum and incubated for 30 min at 37°C in 100 mM Bis-Tris, 100 mM sodium acetate buffer, set at either pH 7 or pH 5. The samples were then analyzed by SDS-PAGE. Similar results were obtained with three independent clones for PC2-(242-248).
quantitative Western blotting as a measure of PC2 protein. The specific activity of the wild-type PC2 preparation was estimated at 35 nmol/h/mg of PC2. The activities of both mutant PC2s varied from 40 to 80% of that of wild-type PC2 in several preparations tested. The reason for this variability is not clear; one possible explanation is differential loss of the enzyme activity during the purification process. It should be noted, however, that if even this is the case, the purification by no means produced unstable PC2 forms, since all three PC2 enzymes retained at least 90% of their initial activity against the fluorogenic substrate after being incubated at 37°C in the reaction buffer for 2 h.
Taken together, these results show that the final activity of the mutant PC2s against the fluorogenic substrate depends heavily on the host cells used for expression. When expressed in AtT-20/27-kDa 7B2 cells, both mutant PC2s exhibited considerably lower activities as compared with wild-type PC2. When PC2s are expressed in CHO/21-kDa 7B2 cells, the activities of the mutant and wild-type PC2s were relatively close.
Binding of 7B2 to Mutant Pro-PC2s Is Greatly Reduced-As was shown above, the rates of maturation of mutant pro-PC2s in AtT-20/27-kDa 7B2/PC2 cells resembled that of wild-type pro-PC2 in AtT-20/PC2 cells expressing no exogenous 7B2. This result could potentially indicate impaired interaction of mutant PC2s with 7B2, since 7B2 is known to play a significant role in the intracellular maturation of pro-PC2 (32, 34, 35) . Therefore, we next studied binding of 7B2 to the mutant PC2s. Fig. 6A shows the results of an experiment in which radiolabeled extracts obtained from AtT-20/27-kDa 7B2 cells co-expressing either wild-type PC2, PC2-(242-243), or PC2-(242-248) were immunoprecipitated with antiserum directed against 7B2. It is evident that neither pro-PC2-(242-243) nor pro-PC2-(242-248) were effectively co-immunoprecipitated with 7B2. 21-kDa 7B2 was not also co-immunoprecipitated with pro-PC2-(242-248) (Fig. 6B) or pro-PC2-(242-243) (data not shown) using an antiserum against PC2. We conclude that the ability to bind 7B2 is greatly reduced in both mutants.
Co-expression of 7B2 Is Still Required for the Generation of Enzymatically Active Mutant PC2s in a Constitutive Cell
Line-The intracellular presence of 7B2 is required for the activation of wild-type pro-PC2 in CHO cells (32) . We next performed experiments to investigate whether mutant proPC2s continue to require co-expression of 7B2 to become enzymatically competent. For this purpose, CHO cells not expressing 7B2 were transiently transfected with the plasmids encoding either wild-type or mutant pro-PC2s. No enzymatic activity was detected in the concentrated (10 -16-fold) conditioned medium from the cells, whether the plasmids encoding wild-type or mutant pro-PC2s were used for transfection (not shown). However, the amount of PC2 forms in the medium was very low, as detected by Western blotting (not shown). We therefore performed transient transfection of another constitutive cell line, HEK 293, with the same vectors encoding wildtype or mutant pro-PC2s. Transfection of this cell line resulted in higher expression levels of PC2s, as detected by Western blotting (not shown). However, medium from HEK 293 cells was enzymatically inactive, whether the plasmids encoding wild-type or mutant pro-PC2s were used for transfection (Table  I) . On the other hand, media obtained from HEK 293 cells that were transiently transfected with mutant pro-PC2 expression vectors along with a 21-kDa 7B2 plasmid exhibited readily detectable levels of PC2 activity (Table I) . We thus conclude that mutant pro-PC2s, similar to wild-type pro-PC2, continue to require co-expression of 7B2 in a constitutive cell line, such as HEK 293, for expression of enzymatic activity.
Inhibition of Mutant PC2s with 7B2 CT Peptide Is Diminished-PC2
is the only prohormone convertase inhibited by the 7B2 CT peptide. This peptide represents a nanomolar inhibitor of PC2 (40) . To examine whether the introduced mutations have any effect on this unique PC2 characteristic, we determined the IC 50 values for the inhibition of wild-type and mutant PC2s with the CT peptide. For this experiment, enzymes were partially purified from the conditioned medium of the CHO/21-kDa 7B2 cells expressing these proteins. The data in Table II show that the mutant PC2s exhibit considerably reduced inhibition with the CT peptide. The IC 50 value of PC2-(242-243) was about 50 times higher than that of wild-type PC2. PC2-(242-248), in its turn, was only weakly inhibited with the CT peptide. Even in the presence of as high a CT peptide concentration as 100 M, PC2-(242-248) retained approximately 50% of its activity. These experiments were performed using two different enzyme preparations of each type of PC2 with identical results. Similar results were also obtained with the conditioned media from CHO/21-kDa 7B2/PC2 (wildtype or mutant) cells as well as with conditioned media from the CHO/21-kDa 7B2 cells that had been transiently transfected with plasmids encoding wild-type pro-PC2 or pro-PC2-(242-248). These data clearly demonstrate that residues 242-248 play a critical role in the inhibitory interaction of PC2 with the 7B2 CT peptide. -248) , or no PC2 (control) were plated at 500,000 cells/well in a six-well plate; 2 days later, serum-free medium was placed on the cells for 16 -17 h, and the conditioned medium was then assayed in duplicate for PC2 enzymatic activity. Western blotting indicated roughly comparable expression levels of the three PC2s in the media (not shown), and protein assay indicated similar growth levels of all cell lines used (not shown). The experiment was repeated once with similar results .   FIG. 6 . The ability of both mutant pro-PC2s to bind to 7B2 is highly reduced. AtT-20/27-kDa 7B2 cells expressing either wild-type PC2, PC2-(242-243), or PC2-(242-248) were pulsed for 20 min and chased for 30 min. 7B2 and PC2 were then subjected to co-immunoprecipitation using antiserum against 7B2 (A) or PC2 (B). Similar results were obtained in two experiments and using three independent clones for each mutant. 2 -In order to determine whether the alteration of inhibitory susceptibility extended to other inhibitory sequences, we next examined the inhibition of mutant PC2s with two peptides: a fragment of the murine PC2 propeptide encompassing residues 57-84 and the synthetic hexapeptide Ac-LLRVKR-NH 2 (obtained during a combinatorial library screen; Ref. 51). The PC2 propeptide represents a potent inhibitor of PC2. 2, 3 The hexapeptide Ac-LLRVKR-NH 2 represents an inhibitor of both PC2 and PC1 but inhibits PC1 with a much higher potency than PC2 (K i values of 3.2 and 360 nM, respectively; Ref. 51) . As is evident from Table II, inhibition of both mutant PC2s, but especially of PC2-(242-248), with the PC2 propeptide fragment is substantially reduced as compared with that of wild-type PC2. In contrast, the hexapeptide exhibits approximately the same potency against the mutant PC2s as it does against wild-type PC2. These data (obtained with two different preparations of each PC2) show that PC2 residues 242-248 are essential for the inhibition of PC2 with the PC2 propeptide fragment and the CT peptide but do not significantly affect its inhibition with the synthetic hexapeptide.
Inhibition of Mutant PC2s with a PC2 Propeptide Fragment

and the Hexapeptide Ac-LLRVKR-NH
In Vitro Cleavage of the Internally Quenched Fluorogenic Substrate with PC2-(242-248)-To explore whether the introduced mutations confer PC1-like specificity to PC2, we examined in vitro cleavage of the internally quenched substrate Abz-VPEMEKRYGGFMQ-EDDnp with partially purified PC2 and PC2-(242-248). This peptide represents a good in vitro substrate for PC2 but is not well cleaved by PC1 (20) . The k cat /K m values obtained are presented in Table III . The value for the mutant PC2 is approximately half of that for wild-type PC2. The activity of PC2-(242-248) against the fluorogenic substrate pERTKR-MCA in the same enzyme preparations was decreased to a somewhat lesser degree (20%). Thus, PC2-(242-248) exhibits a decrease in its activity and/or affinity toward the internally quenched substrate as compared with wild-type PC2; however, this difference is not profound, since PC1 is totally unable to cleave this internally quenched substrate. We conclude that the introduction of the PC1 residues does not substantially affect the specificity of PC2 toward this substrate.
Proenkephalin Cleavage with Mutant PC2s in Vivo-In a further attempt to determine if mutant PC2s acquire PC1-like specificity, we studied the cleavage of PE, an opioid peptide precursor. PE has been shown to be processed differentially by PC1 and PC2. While PC1 cleaves this protein predominantly to intermediates of 3-10 kDa in size, cleavage with PC2 yields mainly mature small enkephalins (22, 23) .
We compared the processing of PE by wild-type and mutant PC2s in vivo by assessing the steady-state levels of two PE cleavage products in AtT-20 cells stably expressing PE and either wild-type PC2, PC2-(242-248), or PC2-(242-243). Fig. 7 shows the profiles of Met-enk-Arg-Gly-Leu immunoreactivity for each cell line. In AtT-20/PE cells not transfected with PC2, the major Met-enk-Arg-Gly-Leu-immunoreactive peak is represented by the 5.3-kDa intermediate (which terminates in Met-enk-Arg-Gly-Leu). Transfection of the cells with either wild-type PC2, PC-(242-248), or PC2-(242-243) resulted in the elevated production of Met-enk-Arg-Gly-Leu-immunoreactive peptides eluting in the position of the mature octapeptide. However, no significant differences in the production of this peptide were observed between cells expressing wild-type or mutant PC2s. The molar ratios of the immunoreactivity associated with 5.3-kDa peptide to that of Met-enk-Arg-Gly-Leu were similar in all three cell lines. We performed these experiments with three different clones for each type of PC2, and the following ratios were observed: 1:1, 1:1.5, and 1:2 in cells expressing wild-type PC2; 1:1, 1:2, 1:2 in cells expressing PC2-(242-243); and 1:1, 1:1.4, and 1:2 in cells expressing PC2-(242-248). Thus, these experiments support the idea that the specificity of the mutant enzymes is not shifted to the more limited PC1-like profile, but that the mutants retain PC2-like specificity.
␣-MSH Production in AtT-20/7B2 Cells Expressing PC2-(242-243) or PC2-(242-248)-It
has been previously shown that in AtT-20 cells cleavage of POMC is mediated by PC1 and PC2 in a strict temporal order (12, 24, 25) ; these studies have supported the idea that PC1 cleaves this precursor predominantly during early steps of processing, while PC2 is involved in later cleavages. ␣-MSH is among the products whose yield is strongly enhanced by PC2 expression in AtT-20 cells (24, 25) . To determine whether the mutant PC2s lose the PC2-specific ability to generate ␣-MSH, POMC processing was compared in AtT-20/27 kDa-7B2 cells stably expressing either wild-type PC2, PC2-(242-243), or PC2-(242-248). Fig. 8 shows the results of a pulse-chase experiment in which cell extracts were immunoprecipitated with an antiserum directed against the N-terminal portion of ACTH. Whereas in nontransfected AtT-20/7B2 cells, POMC was cleaved predominantly to ACTH with no detectable trace of ␣-MSH (Fig. 8A) , in cells expressing wild-type PC2, ␣-MSH represented the major labeled peptide (B), and the ␣-MSH/ACTH ratio was approximately 2:1. However, decreased ability to produce ␣-MSH was observed for both mutant PC2s. In cells expressing PC2-(242-248), the peak corresponding to ␣-MSH was 4 -5 times smaller than the ACTH peak (Fig. 8C) . In cells expressing the mutant PC2-(242-243), production of ␣-MSH was elevated, indicating increased activity of this mutant compared with PC2-(242-248), but this peak was still somewhat reduced compared with wild-type PC2 (Fig.  8D) . These experiments were reproduced with two independent clones of each mutant, and quantitatively similar results were obtained. Thus, the PC2 mutants appear to be impaired with regard to the rate of processing of POMC to ␣-MSH. By contrast, using a steady labeling technique in which cells are labeled for 6 h, no significant differences were observed in the steady-state level of POMC products between cells expressing either wild-type PC2, PC2-(242-243), or PC2-(242-248); ␣-MSH represented the major radioactive peak in all three cases (Fig. 9) . Steady labeling results were confirmed using two independent clones of wild-type PC2 and of each mutant PC2. Although the rates of ␣-MSH production obtained in pulsechase experiments showed kinetic differences between POMC processing by mutant PC2s and wild-type PC2, these differences apparently did not result in the accumulation of any changes to the final POMC processing pattern.
DISCUSSION
The subtilisin-like enzymes PC2 and PC1, although sharing over 50% homology in the catalytic domain, exhibit certain differences in their substrate specificities (12, 22-27, 29, 30, 57) . The two neuroendocrine-specific SPCs also exhibit dramatic differences in their profile of inhibition by peptide inhibitors such as the CT peptide (40, 41, 51) . In addition to these differences, PC2, but not PC1, specifically binds to the neuroendocrine protein 7B2 (32, 33, 58) . Comparison of the primary sequences of PC2s, PC1s, and furins within their proposed substrate binding pockets (15, 31) has shown that the sequence in positions 242-248 in PC2s differs considerably from the corresponding sequences in PC1s and furins. Remarkably, all PC1 and furins contain a single amino acid deletion in the amino-terminal portion of this sequence. The only G residue in the sequence, which is invariable in all PC1s and furins, corresponds to the invariable QP residues (positions 242 and 243) found in PC2s. In the present study, we asked whether certain PC2-specific properties are at least in part due to the specific residues occurring in these positions. For this purpose, we constructed two mutants of murine PC2 by replacing residues in either positions 242 and 243 or positions 242-248 with the corresponding residues found in murine PC1.
Our results indicate that while the insertion of PC1 sequence into the PC2 backbone results in the synthesis of catalytically active chimeric enzymes, the mutant PC2s seem not to exhibit profound PC1-like changes in specificity. Processing of proenkephalin in AtT-20/PE cells expressing either wild-type or mutant PC2s resulted in a similar ratio of the PC1 and PC2 cleavage products, and PC2-(242-248) did not exhibit considerable changes in the kinetic constant toward the PC2-specific internally quenched substrate. Some differences were observed in the rate of production of ␣-MSH by wild-type and mutant PC2s. The production of ␣-MSH by PC2-(242-243) and, especially, PC2-(242-248) proceeded at a slower rate as compared with wild-type PC2. This change in rate, however, may result not only from alterations in the substrate specificity of mutant PC2s but also from a somewhat lower presence of the 66-kDa PC2 form (due to the lower PC2/(PC2 ϩ pro-PC2) ratio) found in the cells expressing mutant PC2s as compared with the cells expressing wild-type PC2 (data not shown). In any case, the observed kinetic differences between POMC processing by wild-type and mutant PC2s were apparently not large enough to result in significant differences in the steady-state levels of POMC-derived products in cells expressing the three PC2s. Taken together, these data suggest that the distinct differences in the substrate specificities of PC2 and PC1 do not significantly depend on sequence variations at residues 242-248.
In contrast to the lack of substantial effect on substrate specificity, the ability of pro-PC2-(242-243) as well as pro-PC2-(242-248) to bind to 7B2 (at least to its 21-kDa form) was decreased to a large degree by the mutations introduced. The latter finding indicates that the residue Gln 242 and/or the residue Pro 243 play a critical role in the interaction of PC2 with 7B2. Based on the three-dimensional structural model proposed for furin (50) Both mutant PC2s, when expressed in AtT-20/27-kDa 7B2 cells, exhibit a slow rate of intracellular maturation and substantially reduced enzymatic activity in the conditioned medium as compared with wild-type PC2. Pro-PC2-(242-248) immunopurified from these cells also displays a highly reduced ability for autocatalytic conversion at acidic pH. Since interaction with 7B2 is required for pro-PC2 maturation and activation (32-37, 45), we suggest that these properties of PC2-(242-243) and PC2-(242-248) are at least partially due to impaired interaction of mutants with 7B2. When expressed in CHO/21-kDa 7B2 cells, the mutant PC2s and wild-type PC2 appear to exhibit more similar rates of autocatalytic conversion and more comparable levels of activity against the fluorogenic substrate. One possible explanation for this discrepancy is that CHO/21-kDa 7B2 cells express extremely high quantities of 7B2; thus, mutant pro-PC2s, whose ability to bind 7B2 is greatly impaired, have a much greater potential for interaction with 7B2 in CHO/21-kDa 7B2 cells than do the same mutants expressed in AtT-20/27-kDa 7B2 cells. While their affinity for 7B2 is severely reduced, mutant pro-PC2s most likely do not totally lose their ability to interact with 7B2 (although this interaction was not detectable by co-immunoprecipitation), since mutant pro-PC2s transiently expressed in a constitutive cell line HEK 293 continue to absolutely require co-expression of 7B2 to become enzymatically competent.
Our data clearly indicate that the PC2 residues in positions 242-248 play a crucial role for inhibition of PC2 with its specific inhibitor, the 7B2 CT peptide (40, 41) . Replacement of residues 242-243 with the corresponding PC1 residues resulted in a 50-fold increase in the IC 50 value for the CT peptide, and replacement of the whole stretch resulted in a more than 1000-fold increase. Thus, PC2-(242-248) not only exhibits a highly decreased ability to bind to 7B2 (at least to its 21-kDa form) but also almost totally loses its ability to be inhibited by the 7B2 CT peptide. These data indicate that mutations in the region 242-248 affect both the binding site for 21-kDa 7B2 and the binding site for the CT peptide on the PC2 molecule.
In addition to loss of inhibition by 7B2 CT peptide, the mutant PC2s also exhibited a loss of inhibition with another long PC2 inhibitor, a PC2 propeptide fragment. These data imply that the CT peptide and this PC2 propeptide fragment bind to the same site (or to overlapping sites) on PC2. However, this dramatic alteration in inhibitory susceptibility does not extend to small peptide inhibitors; inhibition of mutant PC2s by the synthetic hexapeptide Ac-LLRVKR-NH 2 (a peptide originally identified during a combinatorial library screen of PC1; Ref. 51) was not significantly altered as compared with wildtype PC2. This hexapeptide represents a much more potent inhibitor of PC1 than PC2 (51) . Because of the competitive nature of this inhibition the hexapeptide most probably binds directly to the substrate binding pockets of PC2 and PC1. The fact that similar inhibition constants were obtained against wild type and the mutant PC2s suggests that mutation of residues 242-248 does not significantly affect the PC2 hexapeptide binding site within the substrate binding pocket. We therefore speculate that inhibition of PC2 with the CT peptide/PC2 propeptide and with the synthetic hexapeptide depends on interaction with separate sites within the PC2 binding pocket. The PC2 site required for inhibition with CT peptide or PC2 propeptide may potentially be located close to, but outside of, the hexapeptide binding region of PC2. Indeed, our previous data support the idea that the inhibitory potency of the CT peptide is at least partially attributable to residue interactions more distal to the hexapeptide binding site, since a synthetic hexapeptide based upon the CT peptide sequence (and including its inhibitory K-K pair) is completely inactive against PC2 (51) . In fact, one of the most conserved portions of 7B2 is the VNPYLQG heptapeptide located 10 -17 residues away from the K-K pair. Taken together, our results imply that residues 242-248 most likely contribute to these distal inhibitory interactions with longer peptide inhibitors.
In conclusion, our data using PC1-substituted mutant PC2s demonstrate that residues 242-248 do not play a significant role in defining the substrate specificity of PC2 but do contribute greatly to binding of 7B2 and are critical for the inhibition of PC2 with the 7B2 CT peptide. Further mutation of catalytic pocket residues will help to identify additional residues that differentiate the cellular biochemistry of these two neuroendocrine SPCs.
